Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Holdings Decreased by Teacher Retirement System of Texas

Teacher Retirement System of Texas decreased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 12.6% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 24,967 shares of the biopharmaceutical company's stock after selling 3,591 shares during the quarter. Teacher Retirement System of Texas' holdings in Regeneron Pharmaceuticals were worth $21,928,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of the business. Principal Street Partners LLC bought a new position in Regeneron Pharmaceuticals in the fourth quarter worth approximately $204,000. Principal Securities Inc. bought a new position in Regeneron Pharmaceuticals in the fourth quarter worth approximately $280,000. Montag A & Associates Inc. grew its stake in Regeneron Pharmaceuticals by 505.9% in the fourth quarter. Montag A & Associates Inc. now owns 927 shares of the biopharmaceutical company's stock worth $814,000 after purchasing an additional 774 shares in the last quarter. Bronte Capital Management Pty Ltd. grew its stake in Regeneron Pharmaceuticals by 2.8% in the fourth quarter. Bronte Capital Management Pty Ltd. now owns 145,421 shares of the biopharmaceutical company's stock worth $127,722,000 after purchasing an additional 3,979 shares in the last quarter. Finally, Wealthspire Advisors LLC grew its stake in Regeneron Pharmaceuticals by 17.5% in the fourth quarter. Wealthspire Advisors LLC now owns 538 shares of the biopharmaceutical company's stock worth $473,000 after purchasing an additional 80 shares in the last quarter. Institutional investors own 83.31% of the company's stock.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, EVP Joseph J. Larosa sold 1,000 shares of the firm's stock in a transaction that occurred on Thursday, February 22nd. The shares were sold at an average price of $967.65, for a total value of $967,650.00. Following the completion of the transaction, the executive vice president now owns 37,543 shares of the company's stock, valued at approximately $36,328,483.95. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other news, EVP Joseph J. Larosa sold 1,000 shares of the firm's stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $967.65, for a total value of $967,650.00. Following the sale, the executive vice president now directly owns 37,543 shares in the company, valued at approximately $36,328,483.95. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Andrew J. Murphy sold 5,783 shares of the firm's stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the completion of the sale, the executive vice president now owns 48,306 shares in the company, valued at $46,203,239.82. The disclosure for this sale can be found here. In the last quarter, insiders sold 8,095 shares of company stock valued at $7,779,766. Company insiders own 8.83% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the company. Bank of America upped their target price on Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the stock an "underperform" rating in a report on Friday, April 12th. Sanford C. Bernstein initiated coverage on Regeneron Pharmaceuticals in a report on Tuesday, March 12th. They issued an "outperform" rating and a $1,125.00 price objective on the stock. Morgan Stanley boosted their target price on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the company an "overweight" rating in a research report on Wednesday, March 13th. StockNews.com cut shares of Regeneron Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Tuesday, April 30th. Finally, UBS Group upped their price target on Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the stock a "buy" rating in a report on Wednesday, April 17th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have given a buy rating to the company. According to data from MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of "Moderate Buy" and an average price target of $981.71.

Regeneron Pharmaceuticals Trading Up 0.6 %

Shares of Regeneron Pharmaceuticals stock traded up $5.80 during mid-day trading on Friday, hitting $973.80. The stock had a trading volume of 351,356 shares, compared to its average volume of 507,505. The company has a quick ratio of 4.51, a current ratio of 5.27 and a debt-to-equity ratio of 0.10. The firm has a market cap of $106.88 billion, a P/E ratio of 28.77, a price-to-earnings-growth ratio of 1.99 and a beta of 0.17. The firm has a 50-day moving average of $941.89 and a two-hundred day moving average of $901.54. Regeneron Pharmaceuticals, Inc. has a 12-month low of $684.80 and a 12-month high of $998.33.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.